Physician profile
Roberto Robinson
NPI 1477655017
$6,282.76
in general payments reported to CMS, 2019-2025
31 companies · $986 in 2025
The $986 reported for 2025 was more than what 90% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,408 · 2020: $518 · 2021: $677 · 2022: $924 · 2023: $684 · 2024: $1,087 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $778.61 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $713.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $629.99 | 2021-2024 | Mavyret |
| Gilead Sciences, INC. | $476.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.69 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $421.46 | 2019-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $345.59 | 2019-2021 | |
| Amgen INC. | $303.18 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $302.86 | 2021-2024 | |
| Exact Sciences Corporation | $248.47 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $213.97 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $208.06 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $158.04 | 2021-2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $147.01 | 2024-2025 | Horizant, Edarbi |
| Agios Pharmaceuticals, INC. | $144.34 | 2024-2025 | Pyrukynd |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $120.85 | 2019 | |
| Pfizer INC. | $114.55 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $109.66 | 2019-2020 | |
| Allergan, INC. | $75.41 | 2019-2020 | |
| Mannkind Corporation | $63.58 | 2019 | |
| Viiv Healthcare Company | $49.23 | 2022 | |
| Glaxosmithkline, LLC. | $41.72 | 2023 | Shingrix, Arexvy, Pediarix |
| Horizon Therapeutics Plc | $31.85 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $23.22 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.62 | 2021 | |
| Biogen, INC. | $21.70 | 2025 | Skyclarys |
| Teva Pharmaceuticals USA, INC. | $18.18 | 2019 | |
| Axsome Therapeutics, INC. | $17.52 | 2025 | Auvelity |
| Hologic Sales and Service, LLC | $15.94 | 2025 | Aptima |
| Myovant Sciences INC. | $15.75 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.